---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-002790"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T02:10:24.201207+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioCryst Q1 ORLADEYO revenue $68.4M (+38% YoY); net loss narrows to $53.3M

## Summary
- ORLADEYO net revenue $68.4M in Q1 2023 (+37.6% YoY); 46% more U.S. patients on therapy vs Q1 2022.
- Over 1,000 U.S. patients on ORLADEYO; new patient start forms up 20% YoY in Q1.
- Full-year 2023 ORLADEYO net revenue guidance set at no less than $320M.
- Entered new $450M loan agreement with Pharmakon; $300M drawn to repay Athyrium debt.
- R&D expense reduced 26% YoY to $48.4M; SG&A rose 39.6% to $47.9M on commercial investment.

## SEC filing metadata
- accession: 0001171843-23-002790
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184323002790/0001171843-23-002790-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184323002790/f8k_050323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-002790
- JSON: https://secwatch.observer/filing/0001171843-23-002790.json
- Plain text: https://secwatch.observer/filing/0001171843-23-002790.txt

## Key facts
- Earnings Releases
  BIOCRYST PHARMACEUTICALS INC reported first quarter ended March 31, 2023 results: revenue $68.8 million, net income Net loss of $53.3 million, or $0.28 per share, EPS $0.28 per share. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2023
  - Revenue: $68.8 million
  - Net income: Net loss of $53.3 million, or $0.28 per share
  - EPS: $0.28 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: For the three months ended March 31, 2023, total revenues were $68.8 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184323002790/0001171843-23-002790-index.htm
- Earnings Releases
  BIOCRYST PHARMACEUTICALS INC updated its full year 2023 guidance (reaffirmed).
  - Period: full year 2023
  - Guidance: reaffirmed
  - Result: guidance update
  source text: The company expects full year 2023 global net ORLADEYO revenue to be no less than $320 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184323002790/0001171843-23-002790-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.